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Axon degeneration precedes cell body death in many age-related neurodegenerative disorders, often
determining symptom onset and progression. A sensitive method for revealing axon pathology could
indicate whether this is the case also in Huntington’s disease (HD), a fatal, devastating neurodegenerative
disorder causing progressive deterioration of both physical and mental abilities, and which brain region
is affected ﬁrst. We studied the spatio-temporal relationship between axon pathology, neuronal loss, and
mutant Huntingtin aggregate formation in HD mouse models by crossing R6/2 transgenic and HdhQ140
knock-in mice with YFP-H mice expressing the yellow ﬂuorescent protein in a subset of neurons. We
found large axonal swellings developing age-dependently ﬁrst in stria terminalis and then in cortico-
striatal axons of HdhQ140 mice, whereas alterations of other neuronal compartments could not be
detected. Although mutant Huntingtin accumulated with age in several brain areas, inclusions in the
soma did not correlate with swelling of the corresponding axons. Axon abnormalities were not a
prominent feature of the rapid progressive pathology of R6/2 mice. Our ﬁndings in mice genetically
similar to HD patients suggest that axon pathology is an early event in HD and indicate the importance of
further studies of stria terminalis axons in man.
Crown Copyright  2014 Published by Elsevier Inc. All rights reserved.1. Introduction
Huntington’s disease (HD) is an age-related, devastating,
autosomal dominant disorder caused by a CAG triplet expansion in
the coding region of the Huntingtin gene (IT15). This results in an
abnormal poly-glutamine (polyQ) stretch in the Huntingtin protein
(HTT) (HDCRG, 1993) and manifests with progressive behavioral,
cognitive and motor abnormalities, and inevitable early death. The
main pathologic hallmark is the selective neurodegeneration of
striatal medium sized spiny neurons, associated with extensive
atrophy of the striatum (Ferrante et al., 1985; Graveland et al.,
1985; Vonsattel et al., 1985). Other affected brain areas includeBY-NC-ND license (http://
he University of Nottingham,
NG7 2UH, UK. Tel.: þ44 115
L. Conforti).
search Campus, Babraham,
te, Wellcome Trust Genome
, London SW170RE, UK.
014 Published by Elsevier Inc. Allcortical layers III and V, globus pallidus, and substantia nigra
(Halliday et al., 1998; Vonsattel et al., 1985). Although striatal and
cortical neuronal loss could underline the overt motor symptoms,
earlier subtle behavioral changes and cognitive abnormalities,
which precede motor symptoms by many years, might be better
explained by neuronal dysfunction (Foroud et al., 1995; Lange
et al., 1995; Lawrence et al., 1996; Mohr et al., 1991). Early
studies on postmortem material from HD patients reported
morphologic alterations in dendritic arbors and spines of medium
sized spiny neurons, as well as in axons, by Golgi impregnation
(Graveland et al., 1985) and immunostaining (Ferrante et al., 1991;
Nihei and Kowall, 1992). Fiber density loss and reduction of frac-
tional anisotropy, which is a measure of white matter integrity,
have been observed in cortex and striatum of early stage HD pa-
tients (Reading et al., 2005; Weaver et al., 2009). Intranuclear
(NIIs) and extranuclear (neuropil) aggregates of N-terminal mutant
huntingtin fragments, produced by abnormal cleavage of the
mutant form of HTT (mHTT), and a microscopic hallmark of HD,
are also found to accumulate in dystrophic corticostriatal axons in
patients (DiFiglia et al., 1997; Sapp et al., 1999). Nuclear inclusions
could be toxic or represent an attempt by the cell to sequester
soluble, more toxic forms of mHTT (Arrasate et al., 2004; Saudourights reserved.
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with neuronal dysfunction (Chen et al., 2001; Davies et al., 1997;
Gutekunst et al., 1999).
The study of the pathologic mechanisms underlining HD is
facilitated by the availability of genetic mouse models, which
reproduce some aspects of the human disease. In particular,
transgenic (TG) R6/2 mice overexpressing a fragment of human
mHTT (Mangiarini et al., 1996) are well characterized and widely
used in preclinical studies. They show extensive atrophy of the
striatum, cortex, and other brain regions as seen with histopatho-
logical techniques (Stack et al., 2005) and with MRI imaging
(Sawiak et al., 2009), but little or no neuronal loss (Li and Li, 2004).
They also show thinner dendrites, reduced dendritic spines
(Klapstein et al., 2001), and early synapse dysfunction and loss,
which may be the structural correlates of the development of
cognitive dysfunction in the asymptomatic phase (Cepeda et al.,
2003; Murphy et al., 2000). Electron microscopy studies estab-
lished the presence of mHTT aggregates in axon terminals and a
reduction of synaptic vesicles (Li et al., 2003). Knock-in (KI) mice
are a genetically more precise HD model as they express
the endogenous mouse HTT protein containing a human HTT
N-terminal fragment with an expanded polyQ stretch (Menalled
and Chesselet, 2002). They display some of the key features of
the human disease with a milder phenotype and slower progres-
sion of the neuropathology compared with TG mice (Menalled,
2005). They show alterations in striatal synaptic activity (Usdin
et al., 1999) and degenerative processes of the axons associated
with the presence of mHTT neuropil aggregates (Li et al., 2001). In
KI mice with 140 CAG repeats (HdhQ140 mice) (Menalled et al.,
2003), reduction in striatal volume, dendrite complexity, and
spine density alterations were reported (Lerner et al., 2012), fol-
lowed by late neuronal loss (Hickey et al., 2008).
Early neurite dystrophies may be caused at least in part by de-
fects in fast axonal transport, an essential process that delivers
newly synthesized molecules from neuronal cell bodies to axons
and synapses. Wild-type HTT plays an important role in fast axonal
transport. It associates with vesicles and favors trafﬁcking of syn-
aptic proteins, organelles and signaling and trophic factors such as
brain-derived neurotrophic factor (Gauthier et al., 2004). Instead,
mHTT disrupts this process in different cellular and animal HD
models (Gunawardena et al., 2003; Trushina et al., 2004), altering
the normal transport of mitochondria (Orr et al., 2008), brain-
derived neurotrophic factor (Wu et al., 2010), and synaptic vesi-
cles and endosomes (Li et al., 2003). mHTT causes a disruption of
JNK pathway and reduces kinesin-1 binding afﬁnity to the micro-
tubules (Morﬁni et al., 2006, 2009). Physical blockade of transport
exerted by the aggregates has also been suggested in cultured
striatal neurons (Li et al., 2001) and in Drosophila (Lee et al., 2004;
Sinadinos et al., 2009).
Although this evidence suggests that axonal dysfunction con-
tributes to HD pathology, it remains unclear in which neuronal
compartment the ﬁrst signs of degeneration occur and the spatial
and temporal evolution of the degenerative changes. To address
this question, we used yellow ﬂuorescent protein (YFP)-H mice,
which express the ﬂuorescent marker protein YFP in a subset of
neurons (Feng et al., 2000), as a tool to investigate axon pathology
in HD models. We introduced the YFP-H transgene in R6/2 hemi-
zygous (Mangiarini et al., 1996) and HdhQ140 heterozygous
(HdhQ140/þ) and homozygous (HdhQ140/Q140) mice (Menalled et al.,
2003) and analyzed time-dependent alterations in the
morphology of individual neuronal compartments, as previously
reported in other models of neurodegeneration (Adalbert et al.,
2009; Crowe and Ellis-Davies, 2013). In the HdhQ140 mice we
detected an age-dependent formation of axonal swellings in the
absence of signiﬁcant changes in cell bodies, dendrites, andsynapses. mHTT aggregate deposition paralleled the formation of
axonal swellings but was topographically divergent. Interestingly,
within the neuronal populations expressing YFP in our model,
increased axonal swellings ﬁrst appeared in the YFP positive axons
of the stria terminalis, and only later in corticostriatal projections. In
contrast, little or no disruption of axonal morphology was detected
in R6/2/YFP-Hmicewhere early synaptic abnormalities were found,
in agreement with previous studies (Cepeda et al., 2003; Klapstein
et al., 2001). Our results highlight important differences in the onset
of pathology of distinct HD mouse models and may help explain
some initial behavioral symptoms. The early axon pathology
observed in stria terminalis in HdhQ140 mice underlines the
importance of studying multiple brain areas in human patients, and
the potential therapeutic value of understanding the mechanisms
leading to axon degeneration in HD.
2. Methods
2.1. Mouse origins and breeding
Hemizygous R6/2 and homozygous HdhQ140 (HdhQ140/Q140)
males (Mangiarini et al., 1996; Menalled et al., 2003) were bred to
female Thy1.2-YFP-H homozygotes on a C57BL/6 background (Feng
et al., 2000) to produce R6/2/YFP-H and heterozygous HdhQ140/
YFP-H (HdhQ140/þ/YFP-H) in the F1 generation. The latter were
then intercrossed to produce mice homozygous for the Q140 mu-
tation and hemizygous for YFP (HdhQ140/Q140/YFP-H). R6/2/YFP-H
mice and YFP-H littermate controls aged 4- and 12-week-old
were used, whereas HdhQ140/YFP-H and YFP-H littermates were
used at 4 and 12 months for heterozygous and at 6 and 12 months
for homozygous mice. All mice were obtained from The Jackson’s
laboratories (Bar Harbor, ME, USA) and kept at the Babraham
Institute in Cambridge and at the University of Nottingham. All
breeding and procedures were performed as authorized under the
Animals (Scientiﬁc Procedures) Act 1986, under project licenses 80/
2254, 40/3576, and 40/3482.
2.2. Genotyping
Tail tips or ear biopsies of 10-day-old mice were collected under
isoﬂurane anesthesia. DNA was extracted from biopsies and geno-
typing was performed by polymerase chain reaction using the
following forward (for) and reverse (rev) primers according to The
Jackson’s Laboratory Protocols (http://www.jax.org/):
R6/2
for: 50- CCGCTCAGGTTCTGCTTTTA-30
rev1: 50-TGGAAGGACTTGAGGGACTC-30
rev2: 50-GGCTGAGGAAGCTGAGGAG-30
HdhQ140
for1: 50-CATTCATTGCCTTGCTGCTAAG-30
rev1: 50-CTGAAACGACTTGAGCGACTC-30
for2: 50-GATCGGCCATTGAACAAGATG-30
rev2: 50-AGAGCAGCCGATTGTCTGTTG-30
For YFP genotyping, primers used were as follows:
for: 50-CGAACTCCAGCAGGACCATGTGA-30
rev: 50-CTTCTTCAAGGACGACGGCAACT-30
R6/2 and HdhQ140 DNA samples were sent to Laragen Inc
(Culver City, CA, USA) for CAG repeat sizing.
Fig. 1. HD mice show enlargement of the lateral ventricle. H&E stained coronal brain sections (20 mm) of 3-month-old R6/2/YFP-H and 6- and 12-month-old HdhQ140/Q140/YFP-H
mice and corresponding YFP-H control littermates. Sections from 4 different anteroposterior brain levels were matched between HD and control mice and imaged (1.25) for
analysis of gross brain morphology (see Section 2). The area of the lateral ventricle was then measured for each section as described in Section 2. Representative sections from each
genotype, brain level, and age are shown. Scale bar, 330 mm. See Table 1 for quantiﬁcation. Abbreviations: HD, Huntington disease; YFP, yellow ﬂuorescent protein.
M. Marangoni et al. / Neurobiology of Aging 35 (2014) 2382e239323842.3. Histology and immunohistochemistry
R6/2/YFP-H and HdhQ140/YFP-H mice, together with the cor-
responding YFP-H littermate controls, were perfused transcardially
with 4% phosphate-buffered paraformaldehyde and brains
dissected and processed as previously described (Adalbert et al.,
2009). Brains were postﬁxed by overnight immersion in the same
ﬁxative and then cryoprotected in 30% sucrose at 4 C for at least
48 hours before sectioning. Free-ﬂoating 50 mm sagittal and 20 mm
coronal brain sections were later obtained using a Leica CM1850
cryostat. For evaluation of gross brain morphology, 20 mm coronalTable 1
Lateral ventricle areas were measured using Volocity 6.1 software in coronal brain sectio
HdhQ140/Q140 and corresponding control littermates
Age (mo) Brain region
(anteroposterior axis)
WT (n)(mm2, mean  SEM)
3 I 13 (293,072  27,844)
II 9 (526,545  20,375)
III 6 (978,491  79,757)
IV 11 (756,578  35,586)
6 I 10 (235,160  29,300)
II 9 (482,997  62,436)
III 9 (1.018eþ006  42,237)
IV 8 (657,449  49,223)
12 I 11 (373,382  46,166)d,e
II 11 (839,953  57,302)e,f
III 9 (1.282eþ006  31,097)f,g
IV 11 (743,956  73,181)d,e
A signiﬁcant increase was found in all the 4 brain areas considered in R6/2 and HdhQ140
Student t-test). A signiﬁcant enlargement was also found within control mice at 12 m
Bonferroni post hoc test) and to 6 months (n ¼ 3, mean  SEM, 1-way ANOVA followed
Key: ANOVA, analysis of variance; SEM, standard error of the mean; WT, wild type.
a p < 0.01.
b p < 0.05.
c p < 0.001.
d p < 0.01.
e p < 0.001.
f p < 0.001.
g p < 0.01.sections were mounted on Superfrost slides (BDH), air-dried and
stained with Hematoxylin and Eosin (H&E) (Lillie, 1965). For
morphologic analysis of YFP expressing (YFPþ) neurons (Adalbert
et al., 2009), 50 mm sagittal sections were incubated for 10 mi-
nutes with nuclear staining Hoechst 33258 diluted in phosphate-
buffered saline (PBS) with 1% Triton (Invitrogen, 1:500), washed 3
times in PBS and then mounted onto Superfrost slides in Vecta-
shield mounting medium (Vector Laboratories).
For immunohistochemistry, 20 mm coronal sections were incu-
bated in PBSwith 1%Triton for 10minutes,washed 3 times in PBS and
then blocked for 1 hour at room temperature (RT)with 3% BSA in PBS,ns of 4 different brain levels (IeIV) of 3-month-old R6/2 and 6- and 12-month-old
R6/2 (n)(mm2, mean  SEM) HdhQ140/Q140 (n)(mm2,
mean  SEM)
13 (579573  81,474)a
9 (760,064  59,105)a
6 (1.367eþ006  99,906)b
11 (1.050eþ006  73,208)a
10 (401,635  22,087)a
9 (853,790  71,517)a
9 (1.549eþ006  61,988)c
8 (1.007eþ006  108,675)b
11 (489,113  64,883)
11 (851,451  62,147)
9 (1.412eþ006  37,081)b
11 (1.034eþ006  91,635)b
/Q140 compared with control mice, at all time points (n ¼ 3, mean  SEM, unpaired
onths compared with 3 months (n ¼ 3, mean  SEM, 1-way ANOVA followed by
by Bonferroni post hoc test).
Fig. 2. The number of striatal neurons in HD mice is unaltered compared with controls. (A) The number of Nissl positive neurons was evaluated in coronal brain sections (20 mm) of
HD/YFP-H mice and corresponding YFP-H control littermates. (a) Representative ﬂuorescent image (2.5) of a coronal brain section showing the 3 striatal ﬁelds (red boxes) acquired
per each section for quantiﬁcation of neuronal number (see Section 2). Scale bar, 100 mm. (b) Representative confocal image (40) of a Nissl stained section corresponding to one of
the ﬁelds quantiﬁed. Scale bar, 20 mm. Green: YFP, red: Nissl, blue: DAPI. (BeD) Quantitative analysis shows no signiﬁcant cell loss in 3-month-old R6/2/YFP-H (B), 12-month-old
HdhQ140/þ/YFP-H (C), and 6- and 12-month-old HdhQ140/Q140/YFP-H (D) compared with the relative controls (n ¼ 3e6, mean  SEM, unpaired Student’s t test and 1-way ANOVA
followed by Bonferroni post hoc test). Abbreviations: ANOVA, analysis of variance; HD, Huntington disease; SEM, standard error of the mean; YFP, yellow ﬂuorescent protein.
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tingtin (Chemicon clone EM48, 1:100, Billerica, MA, USA). Goat anti-
mouse Alexa Fluor 568 (Invitrogen, 1:200, Paisley, Scotland, UK) was
used as secondary antibody (Adalbert et al., 2009). After incubation in
secondary antibody, sections were mounted onto Superfrost slides in
VectashieldmountingmediumcontainingDAPI (Vector Laboratories).
To stain neuronal cell bodies, 20 mm coronal sections were
incubated with NeuroTrace ﬂuorescent Nissl stain in PBS (Invi-
trogen-Molecular Probes, 1:300; Peterborough, UK) in PBS for
20minutes and thenwashed in PBS for 2 hours at room temperature
before being mounted on slides in Vectashield containing DAPI.2.4. Western blot
Western blot was carried out as previously described (Conforti
et al., 2007). Fresh frozen striata and cortices from R6/2, HdhQ140,
andwild-type littermatemicewere homogenized in RIPA lysis buffer
containing protease inhibitors (Complete mini, Roche; West Sussex,
UK), protein samples loaded on a 10% SDS polyacrylamide gel, and
then transferred to nitrocellulose membrane using a semi-dry blot-
ting apparatus (BioRad; Hertfordshire, UK). Membranes were then
blocked for 1 hour in 5% BSA in PBS plus 0.2% Tween-20 (PBST),
incubated overnight with primary antibody in 5% BSA in PBST at 4 C
and subsequently incubated for 1 hour at RT with HPRT-linked sec-
ondary antibody in 2% BSA in PBST. The following primary antibodies
wereused:mouse anti-synaptophysin (Dako cloneY38,1:10,000; Ely,
UK) and mouse anti-PSD-95 (Abcam, 1:2000; Cambridge, UK). Asloading control, mouse anti-b-tubulin III was used (Sigma, 1:5000;
Gillingham, UK). Bands were visualized on ﬁlm using a chemilumi-
nescent detection kit (GE Healthcare; Amersham, UK).2.5. Imaging and quantitative analysis
H&E stained sections were imaged by low power (Plan-NEO-
FLUOAR 1.25X/0.035) light microscopy (Zeiss Axioplan), and the area
of the lateral ventricle was measured using Volocity 6.1 software.
Sections representative of 4 different anteroposterior brain areas
werematchedbetweencontrol andHDmiceandused for theanalysis.
For analysis of all ﬂuorescently labeled sections, z-stack images
were acquired by confocal microscopy (Zeiss LSM 710 Laser Scanning
Microscope) at 1 airy unit with the following excitation/emission ﬁl-
ters: DAPI/Hoechst 405 nm/420e480 nm, YFP 488 nm/505e550 nm,
AlexaFluor 568 andNeuroTrace561nm/575e615nm.All quantitative
analyses on confocal images were performed manually using ImageJ
software, on maximum projection images resulting from the super-
imposition of the single z-stacks.
In particular, for morphologic characterization of YFPþ neurons
and axons, confocal images were acquired with a 20 air-objective
(Plan-Apochromat 20/0.8) and axonal swellings quantiﬁed in 3
images per section, corresponding to cortex, striatum dorsal, and
striatumventral, in 3 sections per animal (n¼ 3e6, Fig. 3B). A cutoff of
approximately 5 mm was used for swelling quantiﬁcation and the
analysiswas carried out independently by 2 different persons, at least
one of whom blinded to the mouse genotype (Bridge et al., 2009).
Fig. 3. R6/2 mice have normal cell bodies and no obvious axon abnormality. Sagittal brain sections (50 mm) of R6/2/YFP-H mice and corresponding YFP-H control littermates were
imaged with confocal microscopy (20) for analysis of axon morphology. (A) Mice aged 4- (aeb) and 12-week-old (ced) show morphologically intact YFPþ neurons and projections
both in cortex (aec) and striatum (bed). Arrows indicate continuous axonal tracts in cortex and striatum. Scale bar, 50 mm. (BeC) Quantiﬁcation of the occasional swellings in cortex
(red box), dorsal (white continuous box), and ventral (white-dashed box) striatum shows a tendency to an increase in R6/2/YFP-H mice compared with controls albeit with no
signiﬁcant difference (n ¼ 4, mean  SEM, 1-way ANOVA followed by Bonferroni post hoc test). Scale bar, 100 mm. (D) Confocal images (40) of YFPþ cortical neurons of YFP-H (a)
and R6/2/YFP-H (b) mice in sagittal brain sections stained with Hoechst show no gross morphologic changes in cell body morphology and (E) quantiﬁcation of their nuclear size
reveals no difference between the 2 genotypes (n ¼ 4, mean  SEM, unpaired Student’s t test). Green: YFP, blue: Hoechst. Scale bar, 20 mm. Abbreviations: ANOVA, analysis of
variance; SEM, standard error of the mean; YFP, yellow ﬂuorescent protein.
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confocal images were acquired using a 63 oil-immersion objective
(Plan-Apochromat 63/1.40). Colocalization studies were per-
formed using Volocity 6.1 software, which allows 3D reconstruction
of maximum projection images.
For analysis of nuclear size of Hoechst stained 50 mm
sagittal sections in cortex and amygdala, a 40 oil-immersion
objective (Plan-Apochromat 40/1.3) was used and quantiﬁ-
cation was performed in 3 different brain sections per animal
(n ¼ 4e6). In the amygdala, a 0.035 mm2 box was randomly
placed within the imaged section and size of Hoechst stained
nuclei of YFPþ cell bodies was measured within it (Adalbert
et al., 2009).
Nissl stained sections were imaged at 40 and the number of
Nissl positive neurons was quantiﬁed in 3 different striatal ﬁelds
per section, in 3 sections per animal (n ¼ 4e6, Fig. 2A).
WB bands were analyzed using ImageJ gel analysis software. For
each band, the relative density wasmeasured and then the adjusted
density value, referred to the b-tubulin III loading control for each
sample, was calculated.
2.6. Statistical analysis
Analysis and graphs were obtained using Prism GraphPad 5.0
software. Datawere analyzed using Student’s t test for independent
samples and 1-way analysis of variance followed by Bonferroni post
hoc test for multiple comparison. Data were expressed as mean 
standard error of the mean and considered statistically signiﬁcant
when p-value was <0.05.3. Results
3.1. R6/2 and HdhQ140 mouse brain shows an age-dependent
enlargement of the lateral ventricle but no striatal neuronal loss
To assess neuropathology in our HDmicewe ﬁrst looked at gross
alterations in brain morphology in H&E stained sections. We
compared matching sections representative of 4 different ante-
roposterior brain levels. In YFP-H control mice, the area of the
lateral ventricle in sections representative of all 4 levels increases
during aging, becoming signiﬁcantly larger at 12 months of age
compared with 3 and 6 months. Instead, there is no difference
between 3 and 6 months of age (Fig. 1 and Table 1). Consistent with
previous studies describing brain atrophy in R6/2 (Aggarwal et al.,
2012; Sawiak et al., 2009) and HdhQ140/Q140 mice (Lerner et al.,
2012), our results showed a signiﬁcant enlargement of the lateral
ventricle in 3-month-old R6/2 and 6- and 12-month-old HdhQ140/
Q140 mice compared with control littermates (Fig. 1 and Table 1).
To investigatewhether thiswasbecauseofneurodegeneration,we
determined the number of neurons in sections of R6/2 and HdhQ140
mouse brain striatum stained with Nissl dye (Fig. 2). Although with
differences to the human phenotype, the striatum of HD mouse
models remains the brain area where most neuropathological hall-
marks, such as deposition of mHTT aggregates, have been described
(Davies et al., 1997; Hickey et al., 2008) and where any potential
neurodegeneration is most likely to be detected. We counted the
number of Nissl stained neurons in striatal sections of 12-week-old
R6/2 (Fig. 2B), 12-month-old HdhQ140/þ (Fig. 2C), and 6- and 12-
month-old HdhQ140/Q140 (Fig. 2D) mice and found no signiﬁcant
M. Marangoni et al. / Neurobiology of Aging 35 (2014) 2382e2393 2387reduction compared with their control littermates. These results are
consistent with previous evidence that HDmousemodels show little
or no neuronal loss at least until very late time points (Davies et al.,
1997; Hickey et al., 2008) and suggest that more subtle changes pre-
ceding cell death might account for brain atrophy. In support of this,
dendritic and synaptic abnormalities have been reported in HD pa-
tients and mouse models (Nithianantharajah and Hannan, 2013).
3.2. Axon swelling is an early feature of HdhQ140/Q140 mice
We then analyzed themorphology of corticostriatal neurons and
axons of R6/2 and HdhQ140mice crossed with YFP-Hmice. Because
of the restricted expression of the ﬂuorescent protein, the YFP-H
mouse line allows longitudinal tracing of individual neurons
running from the cortical layer V toward the striatum passing
through the corpus callosum and therefore enables visualization of
all structures of these neurons, from dendrites to cell bodies to the
long projection axons (Adalbert et al., 2009).Fig. 4. Axonal swellings are detected in HdhQ140/Q140 mice before changes in cell bodies and
old WT/YFP-H (aec) and HdhQ140/þ/YFP-H (def) mice, from (B) 6-month-old WT/YFP-H (
HdhQ140/Q140/YFP-H (def) mice, show increased axonal swellings in the KI model compared
cortex and striatum dorsal and ventral reveals a signiﬁcant increase in the striatum of Hd
detected in HdhQ140/Q140 at 6 months, whereas in HdhQ140/þ mice at 12 months we could det
SEM, 1-way ANOVA followed by Bonferroni post hoc test, * p < 0.05, ** p < 0.01, compared
stained with Hoechst in the cortex of (a) 12-month-old HdhQ140/Q140 and (b) control YFP-H
nuclear areas did not show gross difference between the genotypes. (G) Dendrite morpholog
(b). (H) Quantiﬁcation of (a) dendrite diameter and (b) spine density over 50 mm (red bar in G
mean  SEM, Student’s t test). Scale bar, 20 mm. Green: YFP, blue: Hoechst. Abbreviations: AN
YFP, yellow ﬂuorescent protein.We ﬁrst analyzed brain sections of 4- and 12-week-old R6/2/
YFP-H mice corresponding to early and late stages of the disease
in this mouse model (Mangiarini et al., 1996). At both time points,
most ﬂuorescent axons of R6/2/YFP-Hmice looked morphologically
normal and did not show signs of degeneration such as swellings or
spheroids, typical features of the central nervous system axonal
dysfunction during normal aging and in many disorders (Bridge
et al., 2009; Ferguson et al., 1997; Galvin et al., 1999; Tsai et al.,
2004) (Fig. 3A). We found a limited number of swellings in both
R6/2 and control mice within the YFP expressing neurons, with a
non-signiﬁcant trend to an increase in the R6/2 mice (Fig. 3B and C).
Moreover, no signiﬁcant reduction in nuclear size of YFPþ cortical
neurons stained with Hoechst was detected in these mice sug-
gesting that the health status of the cell bodies was good (Adalbert
et al., 2009) (Fig. 3D and E).
Next,weanalyzedbrain sectionsof4-and12-month-oldHdhQ140/þ
mice corresponding to early and advanced stage in this model, which
carries the mutation in the appropriate genomic and protein contextdendrites. Confocal images (20) of sagittal brain sections (50 mm) from (A) 12-month-
aec) and HdhQ140/Q140/YFP-H (def) mice and (C) 12-month-old WT/YFP-H (aec) and
with the controls. Scale bar, 50 mm. (D) Quantiﬁcation of the number of swellings in
hQ140/Q140 mice compared with controls at 12 months of age. No difference could be
ect a trend to an increase although it was not statistically signiﬁcant (n ¼ 3e6, mean 
with the corresponding WT). (E) Confocal images (40) of YFPþ neurons with nuclei
mice show no gross morphologic changes. Scale bar, 20 mm. (F) Quantiﬁcation of their
y appears normal in 12-month-old HdhQ140/Q140 (a) compared with YFP-H control mice
: a, b) shows no signiﬁcant difference in HdhQ140/Q140 mice compared with YFP-H (n ¼ 4,
OVA, analysis of variance; KI, knock in; SEM, standard error of the mean; WT, wild type;
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could not ﬁnd any abnormalities in the KI model compared with
controlmice (not shown).However, interestinglywefoundan increase
in the number of axonal swellings of HdhQ140/þ/YFP-Hmice compared
with YFP-H wild-type mice at 12 months (Fig. 4A) albeit this increase
did not reach a statistically signiﬁcant value (Fig. 4D).
Therefore, to test whether increasing mutant Hdh gene dosage
accentuates the axonal morphologic abnormalities we detected in
the heterozygous HdhQ140 mice, we analyzed YFP expressing
neurons of HdhQ140/Q140 mice at 6 and 12 months of age. Impor-
tantly, homozygotes retain the advantages of normal gene expres-
sion pattern, physiological expression level, and normal RNA
splicing despite differing from human patients in having 2 mutant
copies of the gene. At 6 months, the number of swellings in corti-
costriatal axons was not signiﬁcantly different from that of the
controls and generally lower than that found in 12-month-old
heterozygotes (Fig. 4B and D). However, we observed a striking,
highly signiﬁcant increase in the number of axonal swellings in 12-
month-old HdhQ140/Q140/YFP-H compared with that in YFP-H con-
trols (Fig. 4C and D). Morphologic alterations appeared to be limited
to the axonal compartment as the nuclear size of the YFPþ neurons
remained unaltered (Fig. 4E and F) as well as their gross dendritic
morphology (Fig. 4G and H).
A big increase in axonal swellings in HdhQ140/Q140/YFP-H mice
was detected in axons running through the stria terminalis, a limbic
forebrain structure located in the proximity of the striatum and the
lateral ventricle. Neurons whose axons form this structure are also
YFPþ in our HD/YFP-H mice (Porrero et al., 2010) (Fig. 5A). Upon
quantiﬁcation, the number of axonal swellings in this area in
HdhQ140/Q140 mice resulted to be signiﬁcantly increased compared
with the control mice already at 6 months and was even greater atFig. 5. Increased number of axonal swellings is detected in stria terminalis of HdHQ140/Q140 m
Representative ﬂuorescent image (2.5) of a sagittal brain section; the red box indicates the
bar, 100 mm. Images 20 of stria terminalis of (b) 6-month-old HdhQ140/Q140 and (c) control m
Higher magniﬁcation image reveals that axon continuity is maintained at both sides (white
terminalis of HdhQ140/Q140 at 6 and 12 months of age shows signiﬁcant increase compared
number of axonal swellings in 12-month-old HdhQ140/Q140 mice (a) compared with contr
corresponding cell bodies are located in the amygdala (white arrows). Scale bar, 100 mm. (D)
reveals no signiﬁcant difference between the genotypes (n ¼ 4e5, mean  SEM; 1-way ANO
error of the mean; WT, wild type; YFP, yellow ﬂuorescent protein.12 months (Fig. 5B). The morphology of YFPþ cell bodies located in
the amygdala, an area that contains the cell bodies of the axons
running in stria terminalis (Fig. 5C), appeared generally normal and
their nuclear size was not altered in HdhQ140 compared with
wild-type mice (Fig. 5D); only occasionally we could detect some
dysmorphic cell bodies in a few of the mice, irrespective of the
genotype (data not shown).
Taken together, these results suggest that axon dystrophy pre-
cedes cell body and dendrite abnormalities in the HdhQ140 HD
model. In addition, they suggest that the corticostriatal pathway
may not be the ﬁrst site of degeneration, which can instead origi-
nate in other brain areas. On the other hand, a different sequence of
neuropathological events characterizes the R6/2 model in which
signiﬁcant axonal degeneration could not be detected.
3.3. mHTT inclusions do not correlate with axon pathology
Next, we asked whether axon abnormalities correlate with the
deposition of mHTT aggregates in HD mouse models. First, we
analyzed by confocal microscopy brain sections of R6/2 mice at
4 weeks of age stained with EM48, an antibody widely used to
detect human mHTT in mouse models (Gutekunst et al., 1999). We
conﬁrmed the presence of widespread small NIIs and neuropil ag-
gregates in cortex and striatum at this time point, in addition to
nuclear diffused ﬂuorescence (Fig. 6A, a, b and e). At 12 weeks, NIIs
appeared as one single larger inclusion per nucleus (Fig. 6A, c, d and
f). These ﬁndings are in agreement with an earlier study, which
described the age-dependent deposition of NIIs in the cortex and
the striatum of R6/2 mice (Davies et al., 1997). 3D reconstruction of
confocal images conﬁrmed colocalization between mHTT aggre-
gates and some YFPþ neurons in our models (Fig. 7A andice. (A) Sagittal brain sections (50 mm) of HdhQ140/Q140/YFP-H and WT/YFP-H mice. (a)
brain area of stria terminalis where a great number of axonal swellings was found. Scale
ice show increased swellings in the KI model compared with WT. Scale bar, 50 mm. (d)
arrows) of the swelling. Scale bar, 20 mm. (B) Quantitative analysis of swellings in stria
with control mice. (C) Confocal reconstruction images of sagittal sections show a big
ol littermates (b) in axons running in the stria terminalis (white arrowheads). Their
Quantiﬁcation of the Hoechst stained nuclear area of YFPþ cell bodies in the amygdala
VA, * p < 0.05, ** p< 0.01). Abbreviations: ANOVA, analysis of variance; SEM, standard
Fig. 6. Spatio-temporal characterization of mHTT aggregate formation in HD models. Coronal sections (20 mm) of R6/2/YFP-H and HdhQ140/YFP-H mice. Sections were immu-
nostained with anti-HTT antibody (EM48) and imaged under high-resolution (63) confocal microscopy to characterize mHTT inclusions. (A) R6/2 mice aged 4-week-old show small
intranuclear (arrowhead) and extranuclear (arrow) mHTT aggregates both in (a) cortex and (b) striatum. R6/2/YFP-H mice aged 12-week-old show large intranuclear (arrowhead)
and small extranuclear (arrow) mHTT aggregates both in (c) cortex and (d) striatum. Strong diffused nuclear staining is also visible. (B) HdhQ140/þ/YFP-H mice aged 4-month-old
show small intranuclear (arrowhead) mHTT aggregates in the (b) striatum although no immunostaining is detected in (a) the cortex. HdhQ140/þ/YFP-H mice aged 12-month-old show
a large intranuclear aggregate (arrowhead) in the (d) striatum, and no aggregates in (c) the cortex. (C) HdhQ140/Q140/YFP-H mice at 6 months of age show large intranuclear ag-
gregates (arrowhead) in (b) the striatum and no staining in (a) the cortex. In 12-month-old HdhQ140/Q140/YFP-H mice small extranuclear aggregates appear in the cortex (c, arrow) in
addition to the large NIIs detectable in striatum (d). (eej) enlarged images from the corresponding boxed areas showmHTT aggregates in the nucleus (arrowheads). Scale bar, 20 mm.
Green: YFP, red: mHTT, blue: DAPI. Abbreviations: HD, Huntington’s disease; mHTT, mutant Huntingtin; YFP, yellow ﬂuorescent protein.
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colocalization between the small neuropil aggregates and the YFPþ
axons with this imaging approach (Fig. 7B and Supplementary
Video 2). Thus, neurons of R6/2 mice develop big mHTT intra-
nuclear aggregates and yet maintain normal axon morphology.
In agreement with previous characterizations (Menalled et al.,
2003), the deposition of mHTT aggregates follows a slower time
course in HdhQ140 mice. In the striatum of HdhQ140/þ mice at
4 months of age only small NIIs were detected, whereas no immu-
nostaining was visible in the cortex (Fig. 6B, a, b and g). At this time
point, in contrast to the earlier description from Menalled et al.
(2003), we could not clearly detect neuropil inclusions in striatum
and cortex. At 12 months, striatal NIIs increased in size but still no
immunoreactivity could bedetected in the cortex (Fig. 6B, c, d andh).
In HdhQ140/Q140 mice at 6 months, large NIIs were detected in the
striatum, whereas no immunoreactivity was present in the cortex,
similar to heterozygotes at 12months (Fig. 6C, a, b and i). In addition
to the large NIIs in the striatum, small extranuclear aggregates
appeared in the cortex of HdhQ140/Q140 mice at 12months (Fig. 6C, c,
d and j). Neither in the amygdala nor in the stria terminalis, could
mHTT immunoreactivity be detected in homozygous KI mice (data
not shown).While these data conﬁrm the subtle and progressive onset of
mHTT deposition in our mouse models, they argue against a corre-
lation between mHTT aggregates and the formation of axonal swell-
ings. However, the presence and detrimental role of soluble mHTT in
the abnormal axons cannot be excluded (Arrasate et al., 2004).
3.4. Synaptic abnormalities in HD mouse models
Synaptic transmission is altered in HD and abnormalities have
been described at early time points in HD models (Smith et al.,
2005). To investigate potential synaptic defects in our R6/2 and
HdhQ140 mice and evaluate their temporal pattern of onset in
relation to the axonal abnormalities, we looked at the expression
levels of the presynaptic and postsynaptic marker proteins syn-
aptophysin and PSD-95 by Western blotting.
In R6/2 mice at 12 weeks of age, a late time point in this mouse
model but when axons still look intact (Fig. 3), the levels of both
these synaptic markers appeared signiﬁcantly reduced in the
striatum, whereas no signiﬁcant difference was found in the cortex
(Fig. 8A and B).
Alterations in the level of neither synaptophysin nor PSD-95
were detected in cortex and striatum of HdhQ140/Q140 mice both at
Fig. 7. (A) YFPþ neurons of R6/2mice accumulate mHTT nuclear aggregates. Confocal images (63) of coronal sections (20 mm) of 3-month-old R6/2/YFP-Hmice immunostained with
anti-HTTantibody (EM48). In the cortex,mHTTaggregates colocalizewith the nucleus of YFPþ neurons (arrow) and this is conﬁrmed by3D reconstruction (Supplementary Video 1). (B)
Neuropil mHTT aggregates do not colocalize with YFPþ axons in R6/2 mice. In the striatum, colocalization between mHTT neuropil aggregates and YFPþ axons is not conﬁrmed by 3D
reconstruction (Supplementary Video 2). Scale bar: 20 mm. Green: YFP, red: mHTT, blue: DAPI. Abbreviations: mHTT, mutant Huntingtin; YFP, yellow ﬂuorescent protein.
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12 months in the hypothalamus, one of the main areas where the
axons running in stria terminalis project their synapses (Fig. 8E).Fig. 8. Levels of synaptic markers in HD mouse brains. Western blots of mouse brain homo
and PSD-95. b-tubulin III was used as a loading control in all blots (KDa 50). Blots for (A) syna
week-old R6/2 and WT mice and corresponding quantiﬁcation (right) show no signiﬁcant re
striatum, the level of synaptophysin (A) and PSD-95 (B) are signiﬁcantly reduced compared w
mice at 6 and 12 months of age we found no signiﬁcant difference in the levels of (C) synapt
(E) The levels of synaptic markers in the hypothalamus of 12-month-old HdhQ140/Q140 mic
Bonferroni post hoc test). Abbreviations: ANOVA, analysis of variance; HD, Huntington’s disTaken together, these results suggest synaptic dysfunction is a
prominent feature of disease in R6/2 transgenic mice and this
precedes degeneration of other neuronal compartments. However,genates probed with antibodies against the presynaptic marker protein synaptophysin
ptophysin (KDa 38) and (B) PSD-95 (KDa 95) of cortical and striatal homogenates of 12-
duction of both markers in the cortex of 3-month-old R6/2 compared with WT mice. In
ith WT mice (n ¼ 8, unpaired Student t-test, * p < 0.05, mean  SEM). In HdhQ140/Q140
ophysin and (D) PSD-95 (n ¼ 7e8, 1-way ANOVA followed by Bonferroni post hoc test).
e do not differ from those of control littermates (n ¼ 7e8, 1-way ANOVA followed by
ease; SEM, standard error of the mean; WT, wild type.
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a time when axonal abnormalities are evident, suggesting that the
sequence of neuropathological events can vary depending on the
genetic model.
4. Discussion
The spatio-temporal evolution of axon pathology in HD pa-
tients and mouse models is still not well deﬁned but its eluci-
dation is important to focus the attention on appropriate
therapeutic approaches. Our results suggest that axon degener-
ation precedes death of other neuronal compartments in a model
of HD genetically similar to HD patients and could initiate in
brain areas which have not been described as primary site of
pathology in HD.
In HdhQ140/Q140/YFP-H mice we found a striking increase in the
number of axonal swellings compared with YFP-H mice at 6 and
12 months of age, preceding cell body, dendrite, and synapse
degeneration. Interestingly, axon pathology in this model was
detected ﬁrst in the stria terminalis, a brain area which is a part of
the limbic system and plays a role in fear and anxiety related
behavior. This structure, which is the ﬁrst area to develop axonal
swellings of those that could be visualized using this method, is
not generally considered the primary site of degeneration in HD;
however, recent studies have addressed the involvement of the
limbic system in early behavioral symptoms in HD patients
(Petersen and Gabery, 2012) and mice (Van Raamsdonk et al.,
2005). A recent study describes early-onset defects suggestive of
increased anxiety in HdhQ140 mice (Hickey et al., 2008), consis-
tent with our ﬁndings that degenerative processes in axons are
ongoing in this area. Only at the later time point of 12 months
signiﬁcant axon pathology extends to the corticostriatal axons of
HdhQ140 mice. Axonal swellings in these mice are morphologi-
cally similar to those during normal aging but appear earlier and
their number is signiﬁcantly higher. Importantly, these morpho-
logic abnormalities in HdhQ140 mouse axons seem to be inde-
pendent of mHTT inclusion formation because no aggregate was
detected in YFPþ neurons in the cortex and the amygdala, 2 areas
where the cell bodies of corticostriatal axons and of stria terminalis
axons are located. This suggests that other factors such as the
presence of the toxic undetectable fraction of mHTT could play a
role.
On the basis of our data, we propose that HdhQ140 mice,
which allow the disease process to be studied in the context of an
aging background, more similar to that in human patients, may
represent a more accurate model to study axon degeneration
during HD progression. Indeed, KI mice are genetically more
similar to human HD patients; they have normal life span and
milder phenotype resembling the presymptomatic stage of the
disease in human patients. The combination of full-length mHTT
expression at a physiological level, rather than just mutant N-
terminal fragments as in transgenic models like the R6/2 mouse,
and the slower progression of the disease which allows normal
aging in these mice in parallel with disease onset, possibly
explain the appearance of morphologic signs of axonal degener-
ation. Moreover, our results suggest that a certain level of mHTT
is required to trigger axonal pathology as only homozygous
HdhQ140 mice, and not heterozygotes, exhibit a signiﬁcantly
higher number of swellings compared with control mice at 1 year
of age. In HdhQ140/þ/YFP-H mice at 12 months, the increase in
number of axonal swellings may be in part related to normal
aging and potentially to YFP accumulation in aging animals
rather than to HD pathology, as an increase with respect to earlier
time points was observed both in KI mice and in control litter-
mates with no statistically signiﬁcant difference between thegenotypes. This is consistent with previous observations sug-
gesting that long-term expression of the YFP transgene itself
increases age-related swellings in some axons (Bridge et al.,
2009).
Our results in R6/2 mice conﬁrm previous observations of
synaptic abnormalities in the striatum of these mice (Cepeda
et al., 2003; Klapstein et al., 2001) and we ﬁnd they occur
before cell body or axonal death. These abnormalities could result
either by synaptic degeneration or by synaptic remodeling
(Torres-Peraza et al., 2008). Conversely, axonal swelling and
spheroid formation is not a prominent feature in these mice, nor
is striatal neuronal death. These ﬁndings highlight some limita-
tions of the transgenic model, which does not fully recapitulate
the pathology of human HD. The aggressive phenotype with early
death around 12e15 weeks of age makes the R6/2 mice particu-
larly convenient for preclinical testing and therapy screening but
less suitable for the investigation of the early mechanisms of an
age-related disease that in human patients has late onset and
slow progression.
YFP-H mice are a powerful tool to detect morphologic changes
when crossedwith neurodegenerative diseasemodels and to assess
axon pathology both in the central nervous system and peripheral
nerves. Indeed, in a similar study on a mouse model of Alzheimer’s
disease (Adalbert et al., 2009), axonal swellings in the absence of
any morphologic sign of cell body dysfunction was also observed.
The similarities between our studies suggest analogies in the
sequence of events leading to degeneration in these 2 different
disease models.
In both HD models, we cannot exclude that axon degeneration
occurs in non-YFPþ neurons. Striatal D2 neurons, which are affected
very early in HD progression (Albin et al., 1992; Reiner et al., 1988),
are not ﬂuorescently labeled in the YFP-H mouse line and we
cannot rule out degeneration occurring in these neurons. Immu-
nostaining with an anti-mHTT antibody in R6/2 mice revealed the
presence of both intranuclear and neuropil mHTT aggregates but
only the ﬁrst were found to colocalize with YFPþ neurons. How-
ever, a colocalization and a toxic effect of neuropil aggregates on
axons of non-YFPþ neurons cannot be excluded.
In conclusion, axon pathology was found in the HdhQ140mouse
as a primary event, which may initiate in brain areas other than
those considered most susceptible to mHTT toxicity, whereas cor-
ticostriatal axons are affected at a later stage. Our results also un-
derline important differences in the site where the ﬁrst
abnormalities are observed depending on the HD mouse model
under study. Understanding the mechanism at the basis of axon
pathology is likely to be crucial to alleviate symptom’s onset and
delay progression in HD.Disclosure statement
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